1. Pharmacoeconomic Analysis in R&D Decision Making
Published:October 2011
No.Of Pages:86
Price:US $ 3835
Introduction
This report gives in depth analysis of the ways in which the pharmaceutical industry can
ensure that it collects sufficient data to support health technology assessments for new
products and how it can apply economic analyses to support decision making during the
R&D process.
Features and benefits
* Understand the importance of health technology assessment in reimbursement decisions
and how to optimize data to get a positive outcome.
* Compare different methods that use health economics early in product development and
can enable decisions to be made that will reduce R&D costs.
* Understand how trials can be designed to provide good evidence to support positive
reimbursement decisions.
* Understand the impact of increasing interaction between the various stakeholders in the
reimbursement decision making process.
* Discover the views of experts in the field of pharmacoeconomics including the Associate
Director of the Scientific Advice Programme at NICE.
Highlights
* Pharma companies should think earlier about potential HTA requirements for any new
drug. Understanding patient perspectives, existing practice, including treatment
heterogeneity, unmet needs, and the costs associated with a condition will help to frame
discussions of cost-effectiveness lbefore a new product comes to market.
* Phase III trials can be designed in such a way as to provide data that supports positive
reimbursement decisions. Studies that provide evidence to support reimbursement will
typically include a comparator, be longer, include a broader patient population, and realistic
outcome measures.
* In the light of healthcare reform in the US, discussion of the costs – and cost-
effectiveness – of treatment will be raised more and more frequently. The FDA and Centers
for Medicaid and Medicare Services have announced their intention to work together to
explore a parallel review process.
Browse All Pharmaceuticals Market Research Reports

2. Table Of Contents
About the authors
Disclaimer
EXECUTIVE SUMMARY
Defining pharmacoeconomics
Pharmacoeconomic analysis to support decision making in drug development
Studies to support pricing and reimbursement
Future directions for value-based drug development
Defining pharmacoeconomics
Summary
Defining pharmacoeconomics
Health Technology Assessment
National authorities
Global collaboration for HTA
Assessing value
Pharmacoeconomics in drug development
Pharmacoeconomic analysis to support decision making in drug development
Summary
Introduction
The MATCH project
The Headroom Approach
The Health Economic (HE) Evaluation Tool
Bayesian decision theory and the value of information
Portfolio optimization
Conclusions
Studies to support pricing and reimbursement
Summary
Understanding pharmacoeconomics in early drug development
Cost-of-illness studies
Epidemiological studies
Patient perspectives
Measuring utility
Including health economics in Phase III study designs
Comparators
Study design
Endpoints
Post-approval studies and data analyses
Observational studies
Pragmatic clinical trials
Data synthesis to support HTA
Costs of comparative effectiveness research
Conclusion
Future directions for value-based drug development
Summary
Harmonization of HTA requirements across jurisdictions
Multi-stakeholder dialogue in Europe
The NICE Scientific Advice process
Multi-stakeholder dialogue

3. Cost-effectiveness and the US healthcare system
Private sector
Minimizing the gap between efficacy and effectiveness
Progressive approvals
Pharmacogenomics
Prescribers and patients
Global development teams
Future directions
Appendix
Research methodology
Acknowledgements
Abbreviations
Glossary
References
LIST OF TABLES
Table: Influential HTA and reimbursement authorities in different regions
Table: Potential benefits from innovative medicines
Table: Trials described in approval packages in the US and EU
Table: Possible Phase III study designs to support HTA
Table: Sample sizes for a 3-arm randomized controlled trial or an adaptive Phase III/IV trial
Table: Post-approval study types that support HTA
LIST OF FIGURES
Figure: Evidence required for regulatory approval and reimbursement decisions
Figure: Areas of potential benefit from innovative medicines
Figure: Definitions of the Quality-Adjusted Life-Year and the Incremental Cost-Effectiveness
Ratio
Figure: Decision-making supported by early health economic analysis
Figure: Applying the Headroom method for a regenerative medicine for surgical treatment
of bladder cancer
Figure: An iterative, Bayesian approach to integrating health economic data into the drug
development lifecycle
Figure: Relationship between the size of Phase IIb and the probability of success in Phase
III
Figure: Relationship between the size of Phase IIb and the product’s expected Net Present
Value
Figure: Using health economic evaluation in drug development and post-approval
Figure: Designs of studies for efficacy and effectiveness
Figure: Adaptive Phase III/IV trial design
Figure: Variation acceptance of surrogate outcomes by disease and HTA body
Figure: Costs of different study types
Figure: Evaluation factors influencing reimbursement decisions in Australia and England
Figure: Functions required in Global Development Teams from the early stages of drug
development

4. About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog